Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 2, 2004, Pages 693-701

  Ungsedhapand, Chaiwat ^a   Srasuebkul, Preeyaporn ^a   Cardiello, Peter ^a,b   Ruxrungtham, Kiat ^a,c   Ratanasuwan, Winai ^d   Kroon, Eugene D M B ^a,b   Tongtalung, Metta ^a   Juengprasert, Nittaya ^d   Ubolyam, Sasiwimol ^a   Siangphoe, Umaporn ^a   Emery, Sean ^e   Lange, Joep M A ^b   Cooper, David A ^e   Phanuphak, Praphan ^a,c  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Abacavir; Didanosine; Lamivudine; Stavudine; Triple nucleoside antiretroviral therapy; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; HYDROXYUREA; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACUTE PANCREATITIS; ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HEADACHE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LYMPHOCYTE COUNT; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT; THAILAND; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; RETROSPECTIVE STUDIES; RNA, VIRAL; STAVUDINE; THAILAND; TIME FACTORS; ZIDOVUDINE;

EID: 2542422020     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200406010-00006     Document Type: Article

References (30)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725-1730.
2. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860.
3. Phanuphak P, Cooper DA, Lange JM. Clinical trials in Asia. AIDS. 1998;12(Suppl B):S163-S167.
4. Ruxrungtham K, Kroon ED, Ungsedhapand C, et al. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. AIDS. 2000; 14:1375-1382.
5. Ungsedhapand C, Kroon ED, Suwanagool S, et al. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. J Acquir Immune Defic Syndr. 2001;27:116-123.
6. Kaufmann GR, Bloch M, Zaunders JJ, et al. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS. 2000; 14:959-969.
7. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and the Henry J. Kaiser Family oundation, November 10, 2003. Available at: http://aidsinfo.nih. gov/guidelines/adult/AA_111003.pdf.
8. Farthing C, Khanlou H, Yeh V, et al. Early virologic failure in a pilot study evaluating the efficacy of once daily abacavir (ABC), lamivudine (3TC), and tenofovir DF (TDF) in treatment naive HIV-infected patients [abstract 43]. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13-16, 2003.
9. Gallant JE, Rodriguez A, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV)+ ABC and 3TC: ESS30009 unplanned interim analysis [abstract H-1722a]. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14-17, 2003.
10. Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000; 133:35-39.
11. Servais J, Schmit JC, Arendt V, et al. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort. HIV Clin Trials. 2000;1:17-24.
12. Van Vaerenbergh K, Harrer T, Schmit JC, et al. Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. AIDS Res Hum Retroviruses. 2002;18:419-426.
13. Miller V, Staszewski S, Sabin C, et al. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis. 1999;180: 530-533.
14. Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS. 2001;15:2379-2384.
15. Palella FJ, Jr, Chmiel JS, Moorman AC, et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS. 2002;16:1617-1626.
16. Chen RY, Westfall AO, Mugavero MJ, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis. 2003;37:714-722.
17. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
18. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis. 2000;30(Suppl 2):S177-S184.
19. Vidal C, Garcia F, Gatell JM, et al. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 19:55-60.
20. Morlat P, Marimoutou C, Dequae-Merchadou L, et al. Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. J Acquir Immune Defic Syndr. 2000;23:255-260.
21. Hoesley CJ, Saag MS, Chatham A, et al. Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice. Clin Infect Dis. 2000; 31:1095-1097.
22. Parruti G, Tarquini P, Falasca K, et al. Two-year experience of dual NRTI therapy for HIV infection: analysis of results and factors influencing viral response and long-term efficacy [abstract P103]. Presented at the 5th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2-26, 2000.
23. Delta Coordinating Committee and Delta Virology Committee. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. AIDS. 1999;13:57-65.
24. Skowron G, Street JC, Obee EM. Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:313-319.
25. Manfredi R, Calza L, Chiodo F. Dual nucleoside analogue treatment in the era of highly active antiretroviral therapy (HAART): a single-centre cross-sectional survey. J Antimicrob Chemother. 2001;48:299-302.
26. Carosi G, Castelli F, Pan A, et al. Dual nucleoside analogues antiretroviral therapy may be considered in naïve patients? [abstract 242]. Presented at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 8-11, 2001.
27. Albrecht M, Hammer S, Liou S, et al. Long-term virologic and immune responses in subjects maintained on exclusive nucleoside analog (NRTI)-based therapy in ACTG 364 [abstract 322]. Presented at the 8th Conference on Retroviruses and Opportunistic Infection, Chicago, February 4-8, 2001.
28. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA. 1998;279:1984-1991.
29. Pathipvanich P, Ariyoshi K, Rojanawiwat A, et al. Survival benefit from non-highly active antiretroviral therapy in a resource-constrained setting. J Acquir Immune Defic Syndr. 2003;32:157-160.
30. Jenwitheesuk E, Watitpun C, Vibhagool A, et al. Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002. Ann Clin Microbiol Antimicrob [serial online]. 2003;2:4. Available at: http://www.ann-clinmicrob.com/content/pdf/1476-0711-2-4.pdf.